drugset / Trial / NCT07108270

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

NCT07108270 ↗

Phase 2 Recruiting 30 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.

Timeline

Start
2025-11-27
Primary completion
2030-03-31
Completion
2030-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dostarlimab Monoclonal antibody — —
Background Carboplatin Small molecule — —
Background Paclitaxel Small molecule — —

Indications